DMAC
DiaMedica Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$304.44M
P/E Ratio
—
EPS
$-0.71
Beta
1.00
52W High
$10.42
52W Low
$3.48
50-Day MA
$6.12
200-Day MA
$7.16
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About DiaMedica Therapeutics Inc
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company is headquartered in Minneapolis, Minnesota.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-36.69M |
| Operating Margin | 0.00% |
| Return on Equity | -86.50% |
| Return on Assets | -50.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.88 |
| Price-to-Book | 6.45 |
| Price-to-Sales (TTM) | 66.68 |
| EV/Revenue | 57.48 |
| EV/EBITDA | -0.96 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $53.88M |
| Float | $28.77M |
| % Insiders | 27.74% |
| % Institutions | 37.85% |
Historical Volatility
HV 10-Day
42.48%
HV 20-Day
52.76%
HV 30-Day
48.90%
HV 60-Day
49.63%
HV Rank
29.4%
Volatility is currently contracting
Analyst Ratings
Consensus ($15.50 target)
5
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026